We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+21.76%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$511M
AUM Growth
+$16.2M
Cap. Flow
+$33.5M
Cap. Flow %
6.56%
Top 10 Hldgs %
48.76%
Holding
68
New
20
Increased
11
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
AFIB
Acutus Medical Inc
AFIB
+$22.8M
2
PCVX icon
Vaxcyte
PCVX
+$12.5M
3
TARA icon
Protara Therapeutics
TARA
+$8.12M
4
CRDF icon
Cardiff Oncology
CRDF
+$7.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.73M

Top Sells

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$10.6M
2
QURE icon
uniQure
QURE
+$8.55M
3
APTO
Aptose Biosciences, Inc.
APTO
+$7.38M
4
MTEM
Molecular Templates, Inc.
MTEM
+$6.83M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$6.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$2.38B
$45.5M 8.91%
5,984,200
– –
TARA icon
2
Protara Therapeutics
TARA
$236M
$43.1M 8.42%
2,558,472
+350,000
+16% +$8.12M
ETON icon
3
Eton Pharmaceutcials
ETON
$1.79B
$28.8M 5.62%
3,640,000
– –
CRDF icon
4
Cardiff Oncology
CRDF
$76.7M
$24.6M 4.81%
1,731,600
+1,141,600
+193% +$7.54M
AFIB
5
DELISTED
Acutus Medical Inc
AFIB
$22.4M 4.37%
+749,990
New +$22.8M
CCXI
6
DELISTED
ChemoCentryx, Inc.
CCXI
$19.5M 3.82%
356,000
-5,600
-2% -$301K
NGNE icon
7
Neurogene
NGNE
$758M
$16.6M 3.25%
69,315
-685
-1% -$166K
HROW icon
8
Harrow
HROW
$1.44B
$16.5M 3.24%
2,959,000
+249,000
+9% +$1.49M
CDXS icon
9
Codexis
CDXS
$182M
$16.4M 3.21%
1,400,000
– –
EIDX
10
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$15.9M 3.12%
315,550
– –
PCVX icon
11
Vaxcyte
PCVX
$9.1B
$15.5M 3.02%
+313,000
New +$12.5M
CLDX icon
12
Celldex Therapeutics
CLDX
$3.18B
$14.7M 2.88%
992,000
-79,000
-7% -$925K
MGNX icon
13
MacroGenics
MGNX
$260M
$13.3M 2.6%
527,000
+26,000
+5% +$710K
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$11.4M 2.23%
222,000
– –
STXS icon
15
Stereotaxis
STXS
$147M
$10.8M 2.12%
3,021,436
-490,064
-14% -$1.89M
APTO
16
DELISTED
Aptose Biosciences, Inc.
APTO
$10.8M 2.11%
3,998
-2,958
-43% -$7.38M
ATXI
17
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$10.7M 2.09%
875
-45
-5% -$547K
TGTX icon
18
TG Therapeutics
TGTX
$8.53B
$10.4M 2.04%
390,000
-66,600
-15% -$1.53M
TCON
19
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$10.4M 2.04%
+100,672
New +$5.39M
FBIO icon
20
Fortress Biotech
FBIO
$93.4M
$10.3M 2.01%
255,333
– –
MYOV
21
DELISTED
Myovant Sciences Ltd.
MYOV
$9.59M 1.88%
682,500
– –
CMRX
22
DELISTED
Chimerix, Inc.
CMRX
$9.56M 1.87%
3,841,500
+1,736,500
+82% +$5.13M
MCRB icon
23
Seres Therapeutics
MCRB
$49.7M
$9.49M 1.86%
+16,766
New +$5.58M
SIOX
24
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$9.42M 1.84%
+2,039,100
New +$6.73M
KNSA icon
25
Kiniksa Pharmaceuticals
KNSA
$6.23B
$8.78M 1.72%
338,000
-6,500
-2% -$122K
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2020 Portfolio in Review

As of Q3 2020, Opaleye Management held 68 positions worth $511M, up 3.3% from $495M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Opaleye Management deployed $33.5M of net new capital in Q3 2020, opening 20 new positions and adding to 11 existing holdings. Its largest new stake was Acutus Medical Inc: 749,990 shares worth $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Aptose Biosciences, Inc., an estimated $7.38M trimmed.

  • Opaleye Management's largest Q3 2020 buy was Acutus Medical Inc: 749,990 shares worth $22.4M.
  • Opaleye Management added most to Protara Therapeutics in Q3 2020, an estimated $8.12M increase.
  • Opaleye Management's biggest Q3 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $7.38M.
  • Opaleye Management fully exited Odonate Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $10.6M.
  • Opaleye Management's ten largest holdings make up 49% of its $511M portfolio in Q3 2020.
  • Opaleye Management opened 20 new positions and closed 13 in Q3 2020.
  • Opaleye Management's portfolio value rose 3.3% quarter-over-quarter to $511M.

Based on Opaleye Management's 13F filing for Q3 2020, filed 16 Nov 2020.